Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.

Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MP, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J.

Eur J Haematol. 2013 Sep;91(3):209-18. doi: 10.1111/ejh.12130. Epub 2013 Jul 25.

PMID:
23646898
[PubMed - indexed for MEDLINE]
2.

BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH.

Eur J Haematol. 2013 Aug;91(2):112-21. doi: 10.1111/ejh.12142. Epub 2013 Jun 28.

PMID:
23672350
[PubMed - indexed for MEDLINE]
3.

KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.

Kim HJ, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, Kim DH; L/MDS working party, Korean Society of Hematology.

Ann Hematol. 2013 Jan;92(2):163-71. doi: 10.1007/s00277-012-1580-5. Epub 2012 Sep 28.

PMID:
23053179
[PubMed - indexed for MEDLINE]
4.

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK.

Blood. 2012 Oct 4;120(14):2826-35. doi: 10.1182/blood-2012-06-435669. Epub 2012 Aug 8.

PMID:
22875911
[PubMed - indexed for MEDLINE]
Free Article
5.

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W, Kanz L, Ganser A, Heil G.

J Clin Oncol. 2003 Dec 1;21(23):4413-22.

PMID:
14645432
[PubMed - indexed for MEDLINE]
Free Article
6.

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

Krauth MT, Eder C, Alpermann T, Bacher U, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2014 Jul;28(7):1449-58. doi: 10.1038/leu.2014.4. Epub 2014 Jan 9.

PMID:
24402164
[PubMed - indexed for MEDLINE]
7.

Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.

El-Sharnouby JA, Ahmed LM, Taha AM, Kamal O.

Egypt J Immunol. 2008;15(1):131-43.

PMID:
20306678
[PubMed - indexed for MEDLINE]
8.

Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.

Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, Jurcek T, Jeziskova I, Krejci M, Dvorakova D, Mayer J.

Exp Hematol. 2009 Jun;37(6):659-72. doi: 10.1016/j.exphem.2009.03.004.

PMID:
19463768
[PubMed - indexed for MEDLINE]
9.

Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.

Martín G, Barragán E, Bolufer P, Chillón C, García-Sanz R, Gómez T, Brunet S, González M, Sanz MA.

Haematologica. 2000 Jul;85(7):699-703.

PMID:
10897121
[PubMed - indexed for MEDLINE]
Free Article
10.

Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.

Corbacioglu A, Scholl C, Schlenk RF, Eiwen K, Du J, Bullinger L, Fröhling S, Reimer P, Rummel M, Derigs HG, Nachbaur D, Krauter J, Ganser A, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 10;28(23):3724-9. doi: 10.1200/JCO.2010.28.6468. Epub 2010 Jul 12.

PMID:
20625124
[PubMed - indexed for MEDLINE]
Free Article
11.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H; French AML Intergroup.

Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15.

PMID:
23321257
[PubMed - indexed for MEDLINE]
Free Article
12.

Clinical significance of minimal residual disease in childhood acute myeloid leukemia.

Miyamura T, Sakata N, Okamura T, Yasui M, Inoue M, Yagi K, Sako M, Komada Y, Matsuyama T, Oda M, Park YD, Kawa K.

Int J Hematol. 2004 Apr;79(3):243-9.

PMID:
15168592
[PubMed - indexed for MEDLINE]
13.

[Clinical analysis of acute myeloid leukemia with CBFB-MYH11-positive].

Cao TT, Zhou MH, Yuan L, Wang Q, Dou LP, Xu YY, Wang N, Wang LL, Yu L, Jing Y.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):305-10. doi: 10.7534/j.issn.1009-2137.2013.02.009. Chinese.

PMID:
23628021
[PubMed - indexed for MEDLINE]
14.

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.

Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Østergaard M, Grimwade D, Hokland P.

Blood. 2010 Jan 14;115(2):198-205. doi: 10.1182/blood-2009-04-212530. Epub 2009 Nov 9.

PMID:
19901261
[PubMed - indexed for MEDLINE]
Free Article
15.

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.

Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, O'Brien M, Yin JL, Burnett AK, Linch DC, Gale RE.

Leukemia. 2013 Sep;27(9):1891-901. doi: 10.1038/leu.2013.186. Epub 2013 Jun 20.

PMID:
23783394
[PubMed - indexed for MEDLINE]
16.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2012 Sep 1;30(25):3109-18. doi: 10.1200/JCO.2011.40.6652. Epub 2012 Jul 2.

PMID:
22753902
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.

Narimatsu H, Iino M, Ichihashi T, Yokozawa T, Hayakawa M, Kiyoi H, Takeo T, Sawamoto A, Iida H, Tsuzuki M, Yanada M, Naoe T, Suzuki R, Sugiura I.

Int J Hematol. 2008 Sep;88(2):154-8. doi: 10.1007/s12185-008-0108-1. Epub 2008 Jun 17.

PMID:
18553224
[PubMed - indexed for MEDLINE]
18.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ.

J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.

PMID:
24062400
[PubMed - indexed for MEDLINE]
19.

Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).

Zhang L, Li Q, Li W, Liu B, Wang Y, Lin D, Zhou C, Li C, Wang J, Mi Y.

Int J Hematol. 2013 Jun;97(6):786-92. doi: 10.1007/s12185-013-1344-6. Epub 2013 Apr 24.

PMID:
23613269
[PubMed - indexed for MEDLINE]
20.

A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.

Lane S, Saal R, Mollee P, Jones M, Grigg A, Taylor K, Seymour J, Kennedy G, Williams B, Grimmett K, Griffiths V, Gill D, Hourigan M, Marlton P.

Leuk Lymphoma. 2008 Mar;49(3):517-23. doi: 10.1080/10428190701817266.

PMID:
18297529
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk